Massive dilution is locked in — the immediate issuance of ~11.2M common shares at $0.20 is already pricing in further weakness, but the real overhang is the ~1.59 billion share equivalent in preferred conversion rights. Traders should monitor the proxy statement and stockholder vote; failure to approve conversion will keep the overhang unresolved, while approval will unleash extreme dilution. The company remains a going-concern risk with a $7M market cap, no revenue, and a pre-revenue CAR-T pipeline (IBC101 Phase 1/2a in Korea). Short interest may rise given the structural dilution.
Price Chart
Executive Summary
Liminatus Pharma completed its acquisition of InnocsAI LLC via merger on July 2, 2026. The total consideration consists of 1.6 billion shares of common stock at $0.20 per share ($320M implied value), but actual issuance at closing was capped at 19.99% of pre-merger common stock (11,188,729 common shares), with the remainder (158,881.1271 shares of Series A Convertible Preferred Stock, each convertible into 10,000 common shares) issued as non-voting preferred that requires stockholder approval to convert. The deal introduces massive potential dilution to existing common shareholders and carries execution risk around the preferred conversion vote.
Key Financial Metrics
Key Facts
- Merger completed on July 2, 2026: InnocsAI LLC merged into a new wholly-owned Delaware subsidiary of Liminatus Pharma.
- Total merger consideration: 1.6 billion shares of common stock at $0.20/share, plus Contingent Value Rights (20% of net proceeds from future sale/out-license of acquired assets).
- At closing, 11,188,729 common shares were issued (~19.99% of pre-merger outstanding).
- An additional 158,881.1271 shares of Series A Non-Voting Convertible Preferred Stock were issued, each convertible into 10,000 common shares pending stockholder approval — representing over 1.58 billion potential additional common shares.
- Series A Preferred has no voting rights and is not redeemable; dividends payable on as-converted basis.
- The deal structure allows closing before stockholder approval, with the conversion vote to occur later.
- Registration Rights Agreement grants InnocsAI members piggy-back and Form S-3 registration rights for the Merger Shares.
- Non-compete and non-solicitation agreements executed with key InnocsAI personnel for 2 years post-closing.
- Prior to this filing (June 3), Liminatus closed a warrant inducement exercise generating ~$1.86M in gross proceeds at $0.18/share, with additional warrant overhang of ~20.7 million shares.
- Market cap is ~$7M at the time of this deal.
Financial Impact
The transaction implies a $320M valuation for InnocsAI at $0.20/share, but actual consideration is massively dilutive: the initial ~19.99% common issuance and the preferred conversion rights could expand the share base from roughly 56M pre-merger shares to over 1.64 billion shares (a ~29x dilution). Combined with prior warrant exercises, total potential dilution is extreme.
Risk Factors
- Stockholder approval for preferred conversion is uncertain; without it, the preferred shares remain non-voting and non-convertible, capping near-term supply.
- Nasdaq continued listing risk: the company must maintain compliance post-merger.
- The associated-party transaction (CEO Chris Kim controls a member of InnocsAI) raises governance concerns.
- InnocsAI's lead candidate is still in Phase 1/2a with no commercial revenue.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 9 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-080613 |
| Document: tm2619730d1_ex10-1.htm | 0001104659-26-080613 |
| Document: tm2619730d1_ex3-1.htm | 0001104659-26-080613 |
| Document: tm2619730d1_8k.htm | 0001104659-26-080613 |
| Document: tm2619730d1_ex10-2.htm | 0001104659-26-080613 |
| Document: tm2619730d1_ex3-2.htm | 0001104659-26-080613 |
| Document: 0001104659-26-080613-index-headers.html | 0001104659-26-080613 |
| Document: 0001104659-26-080613-index.html | 0001104659-26-080613 |
| Document: 0001104659-26-080613.txt | 0001104659-26-080613 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 18, 2026 10w ago | 8-K | $0.1117 $0.0678 | ▲ +39.30% | ▲ +38.46% | $2.89 (−2487.29%) |
Jul 6, 2026 16w ago | 8-K | $0.1426 $0.1137 | ▲ +20.27% | ▲ +21.12% | $2.89 (−1926.65%) |
Jun 23, 2026 17w ago | S-1 | $0.1031 $0.1187 | ▲ +15.13% | ▲ +14.46% | $2.89 (+2703.10%) |
May 21, 2026 22w ago | Press Release | $0.1690 $0.1089 | ▲ +35.56% | ▲ +34.15% | $2.89 (−1610.06%) |
Mar 17, 2026 32w ago | Press Release | $0.2300 $0.1860 | ▼ −19.13% | ▼ −23.43% | $2.89 (+1156.52%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers